These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 36826143)

  • 21. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
    Beltran H; Eng K; Mosquera JM; Sigaras A; Romanel A; Rennert H; Kossai M; Pauli C; Faltas B; Fontugne J; Park K; Banfelder J; Prandi D; Madhukar N; Zhang T; Padilla J; Greco N; McNary TJ; Herrscher E; Wilkes D; MacDonald TY; Xue H; Vacic V; Emde AK; Oschwald D; Tan AY; Chen Z; Collins C; Gleave ME; Wang Y; Chakravarty D; Schiffman M; Kim R; Campagne F; Robinson BD; Nanus DM; Tagawa ST; Xiang JZ; Smogorzewska A; Demichelis F; Rickman DS; Sboner A; Elemento O; Rubin MA
    JAMA Oncol; 2015 Jul; 1(4):466-74. PubMed ID: 26181256
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular targets in GI malignancies - A pathologist's perspective.
    Pawar S; Sharma A
    Indian J Pathol Microbiol; 2021 Jun; 64(Supplement):S43-S51. PubMed ID: 34135137
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Accelerating the Development of Personalized Cancer Immunotherapy by Integrating Molecular Patients' Profiles with Dynamic Mathematical Models.
    Agur Z; Elishmereni M; Foryś U; Kogan Y
    Clin Pharmacol Ther; 2020 Sep; 108(3):515-527. PubMed ID: 32535891
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine.
    Nebot-Bral L; Brandao D; Verlingue L; Rouleau E; Caron O; Despras E; El-Dakdouki Y; Champiat S; Aoufouchi S; Leary A; Marabelle A; Malka D; Chaput N; Kannouche PL
    Eur J Cancer; 2017 Oct; 84():290-303. PubMed ID: 28846956
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Programmed cell death protein-1 inhibitors in the treatment of digestive system tumors in Chinese population: an observational study of effectiveness and safety.
    Yang W; Chang L; Guo Q; Chen J; Yu W; Zhang W
    Ann Palliat Med; 2021 Aug; 10(8):9015-9024. PubMed ID: 34488388
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biomarkers for response to immunotherapy in hepatobiliary malignancies.
    Lin ZF; Qin LX; Chen JH
    Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):413-419. PubMed ID: 35973935
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Determining If a Somatic Tumor Mutation Is Targetable and Options for Accessing Targeted Therapies.
    Bruinooge SS; Sherwood S; Grubbs S; Schilsky RL
    J Oncol Pract; 2019 Nov; 15(11):575-583. PubMed ID: 31386607
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
    Shea M; Costa DB; Rangachari D
    Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The changing role of pathologists from morphologists to molecular pathologists in the era of precision medicine.
    Masood S
    Breast J; 2020 Jan; 26(1):27-34. PubMed ID: 31876097
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical management of metastatic colorectal cancer in the era of precision medicine.
    Ciardiello F; Ciardiello D; Martini G; Napolitano S; Tabernero J; Cervantes A
    CA Cancer J Clin; 2022 Jul; 72(4):372-401. PubMed ID: 35472088
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Surgical Options for Peritoneal Surface Metastases from Digestive Malignancies-A Comprehensive Review.
    Eftimie MA; Potlog G; Alexandrescu ST
    Medicina (Kaunas); 2023 Jan; 59(2):. PubMed ID: 36837456
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer.
    Ros J; Baraibar I; Martini G; Salvà F; Saoudi N; Cuadra-Urteaga JL; Dienstmann R; Tabernero J; Élez E
    Curr Treat Options Oncol; 2021 Nov; 22(12):113. PubMed ID: 34741675
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimizing cancer immunotherapy: Is it time for personalized predictive biomarkers?
    Music M; Prassas I; Diamandis EP
    Crit Rev Clin Lab Sci; 2018 Nov; 55(7):466-479. PubMed ID: 30277835
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic significance of pretreatment plasma fibrinogen level in patients with digestive system tumors: a meta-analysis.
    Ji R; Ren Q; Bai S; Wang Y; Zhou Y
    Int J Biol Markers; 2018 Aug; 33(3):254-265. PubMed ID: 29874984
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A single-cell tumor immune atlas for precision oncology.
    Nieto P; Elosua-Bayes M; Trincado JL; Marchese D; Massoni-Badosa R; Salvany M; Henriques A; Nieto J; Aguilar-Fernández S; Mereu E; Moutinho C; Ruiz S; Lorden P; Chin VT; Kaczorowski D; Chan CL; Gallagher R; Chou A; Planas-Rigol E; Rubio-Perez C; Gut I; Piulats JM; Seoane J; Powell JE; Batlle E; Heyn H
    Genome Res; 2021 Oct; 31(10):1913-1926. PubMed ID: 34548323
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human epidermal growth factor receptor 2-positive digestive tumors.
    Wagner AD; Özdemir BC; Rüschoff J
    Curr Opin Oncol; 2019 Jul; 31(4):354-361. PubMed ID: 31170116
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liquid biopsy as a perioperative biomarker of digestive tract cancers: review of the literature.
    Shoda K; Saito R; Maruyama S; Furuya S; Akaike H; Kawaguchi Y; Amemiya H; Kawaida H; Sudo M; Inoue S; Kono H; Ichikawa D
    Surg Today; 2021 Jun; 51(6):849-861. PubMed ID: 32979121
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MiR-139 in digestive system tumor diagnosis and detection: Bioinformatics and meta-analysis.
    Wang YH; Ji J; Weng H; Wang BC; Wang FB
    Clin Chim Acta; 2018 Oct; 485():33-41. PubMed ID: 29883634
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The prognostic significance of UCA1 for predicting clinical outcome in patients with digestive system malignancies.
    Liu FT; Dong Q; Gao H; Zhu ZM
    Oncotarget; 2017 Jun; 8(25):40620-40632. PubMed ID: 28380443
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.
    De Mattia E; Cecchin E; Toffoli G
    Drug Resist Updat; 2015 May; 20():39-70. PubMed ID: 26027741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.